Course information

Evidence-Based Treatment of Intermediate- to Advanced-Stage Hepatocellular Carcinoma: Improving Outcomes With Modern Therapies
Audience: Medical oncologists, hepatologists, gastroenterologists, surgeons, and other healthcare professionals involved in the management of patients with HCC.
Description:

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE credit. Certificates are awarded upon successful completion of the post-test and evaluation form.

Internet Release and Expiration Dates: October 13, 2008 – October 12, 2009

Time to Complete: 60 minutes

In this activity, an expert in liver diseases discusses clinical issues and the latest evidence in the treatment of hepatocellular carcinoma.

Upon completion of this activity, participants will be able to:

  • Perform accurate diagnosis and staging of patients presenting with HCC
  • Select systemic treatment for a patient with metastatic HCC based on the latest evidence and recommendations, and effectively manage treatment-related adverse effects
  • Advise patients with locally advanced HCC regarding optimal selection of locoregional therapies based on the latest evidence on the risks and benefits of different options
Author: Robert G. Gish, MD
Provider: Peer View Press
Author Bio:

Robert G. Gish, MD Medical Director, Liver Transplant Program Chief, Division of Hepatology and Complex GI California Pacific Medical Center San Francisco, California Robert G. Gish, MD, has a financial interest/relationship or affiliation in the form of: Consultant for Amgen Inc.; Anadys Pharmaceuticals, Inc.; Bayer AG; Bristol-Myers Squibb Company; Chiron Corporation; Corixa Corporation; Eximias Pharmaceutical Corporation; F. Hoffmann-La Roche Ltd; Gilead Sciences Medical Affairs; GlaxoSmithKline; GlobeImmune, Inc.; Hepahope, Inc.; Human Genome Sciences, Inc.; Idenix Pharmaceuticals, Inc.; Innogenetics, Inc.; InterMune, Inc.; Merck & Co., Inc.; Metabasis Therapeutics, Inc.; Nucleonics, Inc.; Ortho Biotech, Inc.; Pharmasset, Inc.; Schering-Plough Corporation; SciClone Pharmaceuticals, Inc.; Valeant Pharmaceuticals International; and ZymoGenetics, Inc. Grant/Research Support from Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences Medical Affairs; GlobeImmune, Inc.; Idenix Pharmaceuticals; InterMune, Inc.; Novartis Pharmaceuticals Corporation; Ortho Biotech, Inc.; Pfizer, Inc.; Schering-Plough Corporation; SciClone Pharmaceuticals, Inc.; and Valeant Pharmaceuticals International. Speakers Bureau participant with Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences Medical Affairs; GlaxoSmithKline; Ortho Biotech, Inc.; Salix Pharmaceuticals, Inc.; Schering-Plough Corporation; and Valeant Pharmaceuticals International.
Sponsor: University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. Educational Grant from Bayer and Onyx.
Categories: Registration required, Free
Plan-add Add to learning plan Plan-catalogue Return to Course Catalogue